跳至主要内容
临床试验/NL-OMON41809
NL-OMON41809已完成不适用

Stratifying Risk in Barrett*s Esophagus: A Pilot Study for Biomarker-Based Patient Management - ASGE Biomarkers Study

Academisch Medisch Centrum0 个研究点目标入组 40 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • 1) Able to read, comprehend, and complete the consent form.
  • 2) Aged 18 to 80.
  • 3) Diagnosed with at least 3 centimeters (>3cm) of Barrett*s esophagus AND no dysplasia or low grade dysplasia per review by pathologist.

排除标准

  • 1) Pregnant women.
  • 2) Current use of blood thinners such as coumadin, warfarin, heparin and/or low molecular weight heparin (requires discontinuation of medication 5 days prior to and 6 days after EGD).
  • 3) Known bleeding disorder.
  • 4) Status post partial or complete esophageal resection.
  • 5) Current or past diagnosis of invasive esophageal cancer (previous intramucosal cancer is allowable, if removed by endoscopic mucosal resection with histologically confirmed negative lateral and deep margins).
  • 6) Prior ablative therapy of the esophagus including prior radiofrequency ablation (RFA), photodynamic therapy (PDT), spray cryotherapy, and other ablation therapies. Prior endoscopic mucosal resection (EMR) is acceptable.

研究者

相似试验